**Chief Physician, Associate Professor, Master's Supervisor, Doctor of Medicine** **Visiting Scholar, Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA** **Clinical Expertise:** 1. Surgical Treatment of Colorectal Cancer 2. Personalized Neoadjuvant Therapy for Colorectal Cancer, Organ Preservation and Watch-and-Wait Strategy for Rectal Cancer 3. Hyper-Enhanced Recovery After Surgery (Hyper-ERAS) for Colorectal Cancer 4. Surgical Management of Malignant Bowel Obstruction and Abdominopelvic Metastatic Cancer **Academic Achievements:** * Most frequently invited speaker from China at the American Society of Colon and Rectal Surgeons (ASCRS) Annual Meeting (2009/2014/2020). * Completed 4 provincial/ministerial-level research grants. **Representative Publications:** 1. Wang, L., Zhang, X.Y., et al., Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234). Ann Surg, 2023. 277(4): p. 647-654. 2. Zhang, X.Y., Wang, L et al., Predicting Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Using Deep Learning of Diffusion Kurtosis MRI. Radiology, 2020. 296(1): p. 56-64. 3. Chinese W, Wait Database Research Cooperation G, Chinese Society of Colorectal S, Chinese Medical A, Colorectal Cancer Physician Specialty C, Colorectal Cancer C. [Chinese expert consensus on the watch and wait strategy in rectal cancer patients after neoadjuvant treatment (2024 version)]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2024;27(4):301-15. 10.3760/cma.j.cn441530-20240227-00075. 4. Li, C., et al., Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Chin J Cancer Res, 2022. 34(4): p. 383-394. 5. Chen, P.J., et al., Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02). Gastroenterol Rep (Oxf), 2023. 11: p. goad017.